Im­Check adds $7.1M to Se­ries B, boost­ing de­vel­op­ment of gam­ma delta T cell pro­grams

Nine months af­ter first an­nounc­ing a Se­ries B, French biotech Im­Check re­turned to the ven­ture cap­i­tal well seek­ing a bit more cash.

The com­pa­ny found what it was look­ing for, seal­ing the deal on an ad­di­tion­al $7.1 mil­lion in­vest­ment and clos­ing the Se­ries B at a to­tal of $64 mil­lion. New fund­ing comes sole­ly from BB Pure­os Bioven­tures and will help sup­port an on­go­ing tri­al for its lead can­di­date, as well as boost de­vel­op­ment of the com­pa­ny’s pre­clin­i­cal port­fo­lio of an­ti­body can­di­dates in im­muno-on­col­o­gy, au­toim­mune and in­fec­tious dis­ease in­di­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER